HIV Clinical Trials

Global HIV Clinical Trials Market to Reach US$1.9 Billion by 2030

The global market for HIV Clinical Trials estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$903.4 Million by the end of the analysis period. Growth in the Phase II segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$412.3 Million While China is Forecast to Grow at 7.6% CAGR

The HIV Clinical Trials market in the U.S. is estimated at US$412.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$394.2 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global HIV Clinical Trials Market – Key Trends & Drivers Summarized

Why Are HIV Clinical Trials Expanding? The Push for Next-Generation Therapies & Vaccines

The HIV clinical trials market is witnessing significant advancements as researchers explore innovative therapies, including long-acting antiretrovirals (ARVs), functional cures, and preventive vaccines. With HIV still posing a global health challenge, clinical trials play a vital role in developing new drug formulations, enhancing patient compliance, and reducing transmission rates. Governments, pharmaceutical companies, and non-profit organizations are increasing investments in HIV research to develop novel treatment regimens that improve quality of life for patients and address drug resistance issues.

How Are Cutting-Edge Technologies Enhancing HIV Clinical Research?

The integration of artificial intelligence (AI), genomic sequencing, and CRISPR-based gene editing is transforming HIV clinical trials. AI is being used for patient recruitment, biomarker identification, and predictive modeling, while gene therapy trials are exploring potential long-term viral suppression or eradication of HIV reservoirs. Additionally, mRNA-based vaccine platforms, similar to those used for COVID-19, are emerging as promising candidates for preventive HIV vaccines.

What Role Do Government Initiatives & Global Collaborations Play in Market Growth?

Public-private partnerships and funding from organizations such as UNAIDS, the NIH, the Gates Foundation, and the World Health Organization (WHO) are accelerating HIV clinical research. Governments are introducing regulatory fast-tracking mechanisms to expedite approval processes for promising therapies, while clinical trial diversity efforts are ensuring inclusive representation of different ethnic and geographic populations.

What’s Driving the Growth of the HIV Clinical Trials Market?

The growth in the HIV clinical trials market is driven by multiple factors, including increasing global HIV prevalence, rising demand for long-acting therapies, and continued investment in vaccine research. The shift toward combination therapies—where multiple drug classes are used to prevent viral resistance—is leading to trials focused on optimizing treatment adherence and reducing side effects. Additionally, the rise of injectable and implantable ARVs is reshaping clinical research, as patients seek alternatives to daily oral medications. Advances in nanomedicine and personalized medicine are further supporting the development of targeted HIV treatments that improve viral suppression with fewer side effects. In parallel, HIV prevention strategies, including pre-exposure prophylaxis (PrEP) and antibody-based therapies, are gaining traction in clinical trials as researchers explore non-traditional approaches to reducing transmission rates. Furthermore, decentralized and virtual clinical trial models—enabled by telemedicine, remote monitoring, and digital health platforms—are enhancing patient participation and retention, particularly in low-resource settings where HIV incidence is highest. With continuous advancements in biomedical research, global funding support, and technological innovations, the HIV clinical trials market is poised for sustained growth, with the ultimate goal of achieving functional cures and vaccine breakthroughs in the coming years.

SCOPE OF STUDY:

The report analyzes the HIV Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Phase (Phase I, Phase II, Phase III, Phase IV); Study Design (Interventional Study Design, Observational Study Design, Expanded Access Study Design); Sponsor (Pharmaceutical & Biopharmaceutical Companies Sponsor, Non-Profit Organizations Sponsor, Other Sponsors)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AbbVie Inc.
• AIDS Clinical Trials Group (ACTG)
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Charles River Laboratories International, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc (ViiV Healthcare)
• HIV Vaccine Trials Network (HVTN)
• ICON plc
• IQVIA Holdings Inc.
• Janssen Pharmaceutical Companies (Johnson & Johnson)
• Merck & Co., Inc.
• Parexel International Corporation
• Pfizer Inc.
• PPD, Inc.
• Roche Holding AG
• Sanofi S.A.
• SGS SA
• Syneos Health
• WuXi AppTec

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.